{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:16:00Z","timestamp":1784740560583,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Monoclonal antibodies acting on the calcitonin gene-related peptide (CGRP) or its receptor have changed migraine preventive treatment. Those treatments have led to reconsidering the outcomes of migraine prevention. Available data mostly considered benefits in terms of relative efficacy (percent or absolute decrease in monthly migraine days [MMDs] or headache days compared with baseline). However, not enough attention has been paid to residual MMDs and\/or migraine-related disability in treated patients. In the present study, we aimed at comparing the relative and absolute efficacy of erenumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>ESTEEMen was a collaborative project among 16 European headache centers which already performed real-life data collections on patients treated with erenumab for at least 12 weeks. For the present study, we performed a subgroup analysis on patients with complete data on MMDs at baseline and at weeks 9-12 of treatment. Starting from efficacy thresholds proposed by previous literature, we classified patients into 0-29%, 30-49%, 50-74%, and \u226575% responders according to MMD decrease from baseline to weeks 9-12 of treatment. For each response category, we reported the median MMDs and Headache Impact test-6 (HIT-6) scores at baseline and at weeks 9-12. We categorized the number of residual MMDs at weeks 9-12 as follows: 0-3, 4-7, 8-14, \u226515. We classified HIT-6 score into four categories: \u226449, 50-55, 56-59, and \u226560. To keep in line with the original scope of the ESTEEMen study, calculations were performed in men and women.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of 1215 patients, at weeks 9-12, 381 (31.4%) had a 0-29% response, 186 (15.3%) a 30-49% response, 396 (32.6%) a 50-74% response, and 252 (20.7%) a \u226575% response; 246 patients (20.2%) had 0-3 residual MMDs, 443 (36.5%) had 4-7 MMDs, 299 (24.6%) had 8-14 MMDs, and 227 (18.7%) had \u226515 MMDs. Among patients with 50-74% response, 246 (62.1%) had 4-7 and 94 (23.7%) 8-14 residual MMDs, while among patients with \u226575% response 187 (74.2%) had 0-3 and 65 (25.8%) had 4-7 residual MMDs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present study shows that even patients with good relative response to erenumab may have a clinically non-negligible residual migraine burden. Relative measures of efficacy cannot be enough to thoroughly consider the efficacy of migraine prevention.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01408-w","type":"journal-article","created":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T10:03:42Z","timestamp":1647684222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study"],"prefix":"10.1186","volume":"23","author":[{"given":"Raffaele","family":"Ornello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Baraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Guerzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Lambru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna P.","family":"Andreou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Raffaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Gendolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Barbanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Aurilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Egeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Cevoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Favoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Vernieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Silvestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta Dalla","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mancioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ranieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Latysheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Filatova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuli","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagny","family":"Holle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Ne\u017e\u00e1dal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"\u010ctrn\u00e1ct\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitka","family":"\u0160\u00edpkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Matou\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonsina","family":"Casalena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Maddestra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Viola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giannapia","family":"Affaitati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Adele","family":"Giamberardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pistoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0651-1939","authenticated-orcid":false,"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,19]]},"reference":[{"issue":"7","key":"1408_CR1","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.cell.2018.11.049","volume":"175","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L (2018) CGRP Antibodies as Prophylaxis in Migraine. Cell. 175(7):1719","journal-title":"Cell."},{"issue":"6","key":"1408_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 14(6):338\u2013350","journal-title":"Nat Rev Neurol."},{"issue":"22","key":"1408_CR3","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstrom Y, Broessner G, Bonner JH, Zhang F et al (2017) A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 377(22):2123\u20132132","journal-title":"N Engl J Med."},{"issue":"10161","key":"1408_CR4","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 392(10161):2280\u20132287","journal-title":"Lancet."},{"issue":"6","key":"1408_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 16(6):425\u2013434","journal-title":"Lancet Neurol."},{"issue":"2","key":"1408_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/head.14032","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B et al (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache. 61(2):363\u2013372","journal-title":"Headache."},{"issue":"10","key":"1408_CR7","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1111\/head.13968","volume":"60","author":"S Cheng","year":"2020","unstructured":"Cheng S, Jenkins B, Limberg N, Hutton E (2020) Erenumab in Chronic Migraine: An Australian Experience. Headache. 60(10):2555\u20132562","journal-title":"Headache."},{"issue":"1","key":"1408_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 21(1):61","journal-title":"J Headache Pain."},{"issue":"1","key":"1408_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 21(1):32","journal-title":"J Headache Pain."},{"key":"1408_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fneur.2020.00417","volume":"11","author":"B Raffaelli","year":"2020","unstructured":"Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A et al (2020) Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study. Front Neurol. 11:417","journal-title":"Front Neurol."},{"issue":"Suppl 2","key":"1408_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10072-020-04677-y","volume":"41","author":"A Ranieri","year":"2020","unstructured":"Ranieri A, Alfieri G, Napolitano M, Servillo G, Candelaresi P, Di Iorio W et al (2020) One year experience with erenumab: real-life data in 30 consecutive patients. Neurol Sci. 41(Suppl 2):505\u2013506","journal-title":"Neurol Sci."},{"issue":"1","key":"1408_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","volume":"21","author":"A Russo","year":"2020","unstructured":"Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S et al (2020) Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain. 21(1):69","journal-title":"J Headache Pain."},{"issue":"1","key":"1408_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","volume":"21","author":"A Scheffler","year":"2020","unstructured":"Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M et al (2020) Erenumab in highly therapy-refractory migraine patients: First German real-world evidence. J Headache Pain. 21(1):84","journal-title":"J Headache Pain."},{"issue":"1","key":"1408_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s10194-020-01214-2","volume":"22","author":"J Talbot","year":"2021","unstructured":"Talbot J, Stuckey R, Crawford L, Weatherby S, Mullin S (2021) Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes. J Headache Pain. 22(1):5","journal-title":"J Headache Pain."},{"key":"1408_CR15","first-page":"2):465","volume":"41(Suppl","author":"ED Valle","year":"2020","unstructured":"Valle ED, Di Falco M, Mancioli A, Corbetta S, La Spina I (2020) Efficacy and safety of erenumab in the real-life setting of S. Antonio Abate Hospital's Headache Center (Gallarate). Neurol Sci. 41(Suppl:2):465","journal-title":"Neurol Sci."},{"key":"1408_CR16","doi-asserted-by":"crossref","unstructured":"Khalil M, Zafar HW, Quarshie V, Ahmed F (2014) Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K. J Headache Pain. 15(54)","DOI":"10.1186\/1129-2377-15-54"},{"key":"1408_CR17","doi-asserted-by":"crossref","unstructured":"(2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 38(1):1-211.","DOI":"10.1177\/0333102417738202"},{"issue":"1","key":"1408_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM et al (2020) European headache federation consensus on the definition of resistant and refractory migraine : Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 21(1):76","journal-title":"J Headache Pain."},{"key":"1408_CR19","doi-asserted-by":"crossref","unstructured":"Ornello R, Baraldi C, Guerzoni S, al. e, Collaborators obotE (2021) Gender Differences in 3-Month Outcomes of Erenumab Treatment\u2014Study on Efficacy and Safety of Treatment With Erenumab in Men. Front Neurol.","DOI":"10.3389\/fneur.2021.774341"},{"key":"1408_CR20","volume-title":"The HIT-6(TM): a user's guide","author":"M Bayliss","year":"2002","unstructured":"Bayliss M, Bathenhorst AS (2002) The HIT-6(TM): a user's guide. QualityMetric, Inc., Lincoln, RI"},{"issue":"1","key":"1408_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/0333102419894559","volume":"40","author":"JL Brandes","year":"2020","unstructured":"Brandes JL, Diener HC, Dolezil D, Freeman MC, McAllister PJ, Winner P et al (2020) The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving >\/=50%, >\/=75%, and 100% response. Cephalalgia. 40(1):28\u201338","journal-title":"Cephalalgia."},{"issue":"9","key":"1408_CR22","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1111\/head.13929","volume":"60","author":"G Broessner","year":"2020","unstructured":"Broessner G, Reuter U, Bonner JH, Dodick DW, Hallstrom Y, Picard H et al (2020) The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving >\/=50%, >\/=75%, and 100% Response. Headache. 60(9):2026\u20132040","journal-title":"Headache."},{"issue":"1","key":"1408_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/0333102419877663","volume":"40","author":"P Tfelt-Hansen","year":"2020","unstructured":"Tfelt-Hansen P, Diener HC, Steiner TJ (2020) Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-review. Cephalalgia. 40(1):122\u2013126","journal-title":"Cephalalgia."},{"issue":"5","key":"1408_CR24","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F et al (2021) Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 28(5):1716\u20131725","journal-title":"Eur J Neurol."},{"issue":"1","key":"1408_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10194-018-0946-z","volume":"19","author":"P Martelletti","year":"2018","unstructured":"Martelletti P, Schwedt TJ, Lanteri-Minet M, Quintana R, Carboni V, Diener HC et al (2018) My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 19(1):115","journal-title":"J Headache Pain."},{"issue":"1","key":"1408_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s10194-021-01252-4","volume":"22","author":"S Sacco","year":"2021","unstructured":"Sacco S, Lampl C, Maassen van den Brink A, Caponnetto V, Braschinsky M, Ducros A et al (2021) Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. J Headache Pain. 22(1):39","journal-title":"J Headache Pain."},{"issue":"1","key":"1408_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15360288.2020.1829249","volume":"35","author":"M Armanious","year":"2021","unstructured":"Armanious M, Khalil N, Lu Y, Jimenez-Sanders R (2021) Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis. J Pain Palliat Care Pharmacother. 35(1):1\u20136","journal-title":"J Pain Palliat Care Pharmacother."},{"issue":"2","key":"1408_CR28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","volume":"10","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L et al (2021) Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review. Pain Ther. 10(2):809\u2013826","journal-title":"Pain Ther."},{"issue":"8","key":"1408_CR29","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1093\/pm\/pnab093","volume":"22","author":"F Cohen","year":"2021","unstructured":"Cohen F, Armand C, Lipton RB, Vollbracht S (2021) Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine. Pain medicine (Malden, Mass). 22(8):1857\u20131863","journal-title":"Pain medicine (Malden, Mass)."},{"key":"1408_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.656294","volume":"12","author":"M Silvestro","year":"2021","unstructured":"Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A (2021) Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine. Front Neurol. 12:656294","journal-title":"Front Neurol."},{"issue":"12","key":"1408_CR31","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.1007\/s10072-021-05547-x","volume":"42","author":"T Toni","year":"2021","unstructured":"Toni T, Tamanaha R, Newman B, Liang Y, Lee J, Carrazana E et al (2021) Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series. Neurol Sci. 42(12):5373\u20135376","journal-title":"Neurol Sci."},{"issue":"12","key":"1408_CR32","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1080\/14737175.2020.1825077","volume":"20","author":"S Sacco","year":"2020","unstructured":"Sacco S, Russo A, Geppetti P, Grazzi L, Negro A, Tassorelli C et al (2020) What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group. Expert Rev Neurother. 20(12):1275\u20131286","journal-title":"Expert Rev Neurother."}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01408-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01408-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01408-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T10:03:48Z","timestamp":1647684228000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01408-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,19]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1408"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01408-w","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,19]]},"assertion":[{"value":"27 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study is a pooled analysis of previously collected and\/or published data; informed consent was already provided by patients. The pooled analysis of the ESTEEMen study was approved by the Internal Review Board of the University of L\u2019Aquila with protocol number 07\/2021; approval was shared with all the study centers. Local ethical approval to pool data was obtained if needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RO reports personal fees from Novartis, Teva, and Eli Lilly, and had non-financial relationships with Allergan\/AbbVie, Novartis and Teva. SS reports personal fees and nonfinancial support from Allergan, Abbott, Eli Lilly, Novartis, and Teva; personal fees from Medscape; and other from Bayer, Pfizer, Medtronic, Starmed, Bristol-Myers Squibb, and Daiichi Sankyo. BR reports research grants from Novartis, and personal fees from Allergan, Lilly, Novartis, and Teva. UR received honoraria for consulting and lectures from Amgen, Allergan, Abbvie, Eli Lilly, Lundbeck, Novartis, electroCore, Medscape, StreaMedUp, and Teva, and research funding from the German Federal Ministry of Education and Research and Novartis. GAf reports competing interests with Novartis. MAG reports competing interests with Helsinn Healthcare and Uriach Italy. GL has received speaker honoraria, funding for travel, and honoraria for participation in advisory boards sponsored by Allergan, TEVA, Lilly and Novartis; he has received speaker honoraria and funding for travel from electroCore, Nevro Corp, and Autonomic Technologies. NL reports personal fees from Novartis and Allergan. E\u0410 reports personal fees from Novartis and Teva. CB and SG received honoraria from Allergan, Teva, Eli Lilly and Novartis. DH reports personal fees from Novartis, Teva, Eli Lilly, Allergan, Hormosan, Zuellig Pharma, Bayer. AR received speaker honoraria from Novartis, Teva, and Eli Lilly. SCe received travel grants, honoraria for advisory boards, speaker panels or clinical investigation studies from Novartis, Teva, Lilly, Allergan, Ibsa, Amgen and Lundbeck. VF has received honoraria as speaker or for participating in advisory boards from Eli Lilly, Novartis and Teva. AR has received speaker honoraria from Allergan, Lilly, Novartis and Teva. MSi has received speaker honoraria from Lilly, Novartis and Teva. FV received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Allergan, Eli-Lilly, Novartis, and Teva. PB received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Alder, Allergan, Bayer, ElectroCore, Eli-Lilly, GSK, Lusofarmaco, MSD, Novartis, Stx-Med, Teva, and Visufarma. CA received travel grants from Eli-Lilly, FB-Health, Lusofarmaco, and Teva. MF, AG, SC, JT, TN, D\u010c, J\u0160, ZM, LS, AS, MM, GAl, EDV, AM, AC, SV, CA, and FP report no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}